Olivier Lacombe
Crossject (France) · 17 works · 353 citations · h-index 10
Top works
- Localisation of drug permeability along the rat small intestine, using markers of the paracellular, transcellular and some transporter routes
- Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate
- In VitroPrimary Human and Animal Cell-Based Blood−Brain Barrier Models as a Screening Tool in Drug Discovery
- Validation of a liquid chromatography–mass spectrometry method to assess the metabolism of dextromethorphan in rat everted gut sacs
- Liquid chromatographic–mass spectrometric method to assess cytochrome P450-mediated metabolism of testosterone by rat everted gut sacs
- The Perfused Everted Intestinal Segment of Rat
- The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis
- Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI—Evidence from in vitro and in vivo models
- Oral treatment for mucopolysaccharidosis VI : Outcomes of the first phase IIa study with odiparcil
- MPS VI associated ocular phenotypes in an MPS VI murine model and the therapeutic effects of odiparcil treatment
- Relative Bioavailability Study of Midazolam Intramuscularly Administered with the Needle-Free Auto-Injector ZENEO® in Healthy Adults
- L'absorption intestinale des xénobiotiques : caractérisation chez le rat
- O04 In vivo assessment of prevention of lung fibrosis using the pan-PPAR agonist lanifibranor in the TbRIIDk-fib mouse model of systemic sclerosis
- Characterization of dermatan sulfate and chondroitin sulfate in tissues from a mouse model of mucopolysaccharidosis type VI using UPLC-MS/MS
- In vitro and in vivo activity of IVA336, a potential substrate reduction therapy, in mucopolysaccharidosis models
- 020 Evidence for altered peroxisome proliferator activated receptor (PPAR) pathway activity in a transgenic mouse model of scleroderma (TbRIIDk-fib): analysis of mouse skin, lung and explanted cells
- The PPAR Agonist Lanifibranor Protects Against Right Ventricular Hypertrophy in a Mouse Model of Systemic Sclerosis Associated Pulmonary Hypertension